Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista colombiana de Gastroenterología
versión impresa ISSN 0120-9957versión On-line ISSN 2500-7440
Resumen
GOMEZ-RAIGOSA, Juliana y VALENCIA-SANCHEZ, Natalia. Diagnostic Efficacy of Fecal Calprotectin in Inflammatory Bowel Disease: Systematic Literature Review. Rev. colomb. Gastroenterol. [online]. 2023, vol.38, n.4, pp.430-438. Epub 26-Feb-2024. ISSN 0120-9957. https://doi.org/10.22516/25007440.1060.
Introduction:
Inflammatory bowel disease is a group of pathologies that include ulcerative colitis and Crohn’s disease, which have similar manifestations. Currently, the diagnosis and monitoring of this disease rely mainly on endoscopic studies. Still, this method can hardly be applied to periodic disease monitoring as it is expensive, invasive, and not readily available. Fecal calprotectin is widely known, easy to use, and affordable, and it is currently the best-characterized biomarker for this pathology.
Materials and methods:
The research design is a systematic diagnostic test validation literature review. A search was conducted in different databases using the QUADAS-2 checklist to evaluate the methodological quality.
Results:
The initial search yielded 352,843 articles published chiefly in PubMed, followed by Scopus and Science Direct. After multiple filters, 221 papers were selected and wholly reviewed. They were evaluated with inclusion and exclusion criteria, with 18 articles being chosen.
Conclusions:
Fecal calprotectin is a reliable surrogate marker of endoscopic activity in IBD. However, there is a lack of consensus on delimiting a cut-off point and improving applicability and diagnostic accuracy. Colonoscopy remains the gold standard in all studies.
Palabras clave : Inflammatory bowel disease; fecal calprotectin; approval of diagnostic tests; biomarker; diagnostic efficacy.